A collaborative effort led by The Burnham Institute's Gen-Sheng Feng has created a mouse with improved glucose tolerance and insulin activity in the liver, and generated new findings about insulin-signaling in the liver that could prove useful in understanding the pathogenesis of type 2 diabetes.
A Burnham Institute study has found that one of the cell's largest families of signaling molecules, called ephrins, which are known to regulate the development of nerve cells, also controls nerve cells' ability to engulf critical chemicals and proteins for learning and memory.
A Burnham Institute study has found that a protein known for its role in gene regulation has another important function, that of initiating DNA repair. The study points to new targets for treatment of cancer.
The Burnham Institute has been selected as a "Program of Excellence in Nanotechnology" by the National Heart, Lung, and Blood Institute of the National Institutes of Health.
A collaborative team of scientists has identified inhibitors of the anthrax toxin, termed lethal factor that could be developed into an emergency treatment for exposure to inhalation anthrax.
A research team lead by the Burnham Institute has synthesized and tested a new series of inhibitors that can prevent the type of nerve cell injury and death associated with many neurodegenerative diseases and stroke.
The Burnham Institute will receive $3 M over the next three years from the NIH to develop an "Exploratory Center for Human Embryonic Stem Cell Research". The grant provides funds to support research that will advance understanding of the fundamental biology of human embryonic stem cells.
The National Foundation for Cancer Research has aligned with The Prostate Cancer Foundation to grant $200,000 in seed funding to The Burnham Institute's NCI-designated Cancer Center to develop three-dimensional experimental culture systems that simulate a tumor's micro-environment.
A study reports that a cell-cycle checkpoint protein, known to be activated by an important class of anticancer drugs, may play crucial roles in both the hampering of therapeutic actions and aiding cancer cells to "recover" and start dividing again after treatment with these drugs.
A collaboration has found that an antibody which binds to an unusual sugar molecule residing in the gut halts the inflammation seen in Crohn's disease and other intestinal inflammations. The antibody could prove to be a promising drug target for these common chronic intestinal disorders.
Researchers have provided detailed insights into the early formation of the heart. A team found that two proteins, called Robo and Slit, are required for normal development of the heart and that malfunction of either of these proteins severely impacts the heart's structure, resulting in congenital heart defects.
Researchers have shown that endocrine progenitor stem cells exist in the adult human pancreas, and they have demonstrated that these stem cells can be transformed into insulin-producing cells.
This data provides the first molecular link between NO free radicals and protein misfolding, which is currently thought to be a common pathway in the pathogenesis of virtually all neurodegenerative conditions. Such conditions also include ALS (or Lou Gehrig's disease), Huntington's disease, and many others.
Metabolic syndrome, an aging-associated group of disorders that includes insulin resistance, heart disease and high lipid levels, may be treatable thanks to a newly discovered role for a regulatory gene, according to a team of scientists at the Burnham Institute for Medical Research.
Muscle weakness and fiber deterioration seen in muscular dystrophy can be countered by a class of drugs currently under study for their effects against cancer, a Burnham Institute study has found. Deacetylase inhibitor Trichostatin A restored skeletal muscle mass and prevented the impaired function characteristic of muscular dystrophies.
The Burnham Institute for Medical Research ("Burnham") has established an affiliation with the University of California, Santa Barbara led by internationally-renowned medical researcher Erkki Ruoslahti, M.D., Ph.D, the campus and the Institute announced today.
Researchers have developed nanoparticles that seek out tumors and bind to their blood vessels, and then attract more nanoparticles to the tumor target. Using this system they demonstrated that the homing nanoparticle could be used to deliver a "payload" of an imaging compound, and in the process act as a clotting agent, obstructing as much as 20% of the tumor blood vessels.
Burnham Institute for Medical Research will receive $ 5,925,878 in grants awarded from the California Institute for Regenerative Medicine as part of the first research grants approved under Proposition 71. The Independent Citizen's Oversight Committee approved the allocation of $45 million to fund 72 grants awarded under CIRM's Scientific Excellence through Exploration and Development Grant Program.
A protein known for its ability to "bridge" interactions between other cellular proteins may spur metastasis in breast cancer, the disease's deadliest stage, a study from Burnham Institute for Medical Research has found.
The tiny Drosophila fruit fly may pave the way to new methods for studying and finding treatments for heart disease, the leading cause of death in industrialized countries, according to a collaborative study by the Burnham Institute for Medical Research, UC San Diego (UCSD) and the University of Michigan.
Human embryonic stem cells (hESCs) can treat degenerative diseases safely and effectively, and do so by invoking multiple mechanisms. These were a few of a number of conclusions arrived at by an international collaboration led by Evan Y. Snyder, M.D., Ph.D., to be published in Nature Medicine.
The California Institute for Regenerative Medicine (CIRM) will fund comprehensive research projects directed by Dr. Mark Mercola and Dr. Stuart Lipton of the Burnham Institute for Medical Research (Burnham) with grants totaling more than $6 million.
A team of researchers at the Burnham Institute for Medical Research ("Burnham") has been awarded $7.39 million from the National Institute of Child Health and Human Development of the National Institutes of Health. The funding will support a five-year, multi-project study entitled "Neuron-Glia Communication in Development."
Burnham Institute for Medical Research (Burnham) announced today appointment of the first three recruits who will initiate operations in Orlando, Florida: director of medicinal chemistry, an assistant professor focusing on diabetes research, and vice president, finance and chief financial officer.
The Burnham Institute for Medical Research (Burnham) has recruited Elizabeth Gianini as Vice President, External Relations for Burnham at Lake Nona, Orlando. Ms. Gianini will join Burnham on July 9 from her current position as Chief of Staff to Mayor Richard Crotty.
The California Institute for Regenerative Medicine (CIRM) announced today the award of $3.79 million to the Burnham Institute for Medical Research (Burnham) for development of a collaborative shared laboratory and expansion of the Institute's training courses in stem cell research. Burnham was one of 17 institutions receiving grants from CIRM for a total of more than $50 million.
Researchers at Burnham Institute for Medical Research ("Burnham") have provided the first evidence that gamma-secretase, an enzyme key to the progression of Alzheimer's, acts as a tumor suppressor by altering the pathway of epidermal growth factor receptor (EGFR), a potential treatment target for cancer. Expedited to publication online by Proceedings of the National Academy of Sciences, these findings reveal a limitation of targeting gamma-secretase for treatment of Alzheimer's and potentially other diseases.
The Burnham Institute for Medical Research ("Burnham") announced today creation of "The Donald Bren Presidential Chair" established with a $2.5 million gift from the Orange County philanthropist and businessman. Mr. Bren honors and supports the work of Dr. John C. Reed, Burnham's President and CEO. It is the first funded chair to support the work of a distinguished scientist at Burnham.
Scientists at the Burnham Institute for Medical Research have discovered how HIV/AIDS disrupts the normal replication of stem cells in the adult brain, preventing new nerve cells from forming. Results to be published in Cell Stem Cell report a novel molecular mechanism that inhibits stem cell proliferation and that could possibly be triggered in other neurodegenerative diseases.
A collaborative group from the Burnham Institute in La Jolla, CA and in Japan, report that the herb rosemary contains an ingredient that fights off free radical damage in the brain. The active ingredient in rosemary, known as carnosic acid (CA), can protect the brain from stroke and neurodegeneration that is due to injurious chemical free radicals.
$20 million donation creates collaboration between Burnham Institute for Medical Research and Sanford Health.
Burnham Institute announced that Daniel P. Kelly, M.D. will assume the position of Scientific Director of Burnham at Lake Nona in Orlando, Florida. In that capacity he will guide the scientific direction of Burnham's Orlando facility by forming several research programs related to diabetes, obesity, metabolism and heart disease.
The mission of the Cancer Center at Burnham Institute is to continue to bridge the gap between basic biological research and the anticancer drug discovery work carried out by pharmaceutical companies. These efforts have significantly benefited from the establishment of the San Diego Center for Chemical Genomics at Burnham, one of 10 collaborating centers known as the "Molecular Libraries Screening Centers Network".
Researchers at the Burnham Institute have discovered a new player in the development of a muscle disorder called sIBM. sIBM is the most common muscle disease among those over the age of 50, causing muscles to gradually weaken and waste away. This discovery provides a potential avenue for future diagnostic and therapeutic opportunities for this disease.
Researchers at the Burnham Institute may have found a new option for targeted breast cancer therapy by showing the link between a certain protein and the formation and development of blood vessels that feed breast tumors.
Recent developments at the Burnham Institute - April 2008
Researchers at the Burnham Institute for Medical Research, led by José Luis Millán, Ph.D., have demonstrated in mice the first successful use of enzyme replacement therapy to prevent hypophosphatasia (HPP), a primary skeletal disease of genetic origin. This discovery lays the foundation for future clinical trials for HPP patients.
Burnham Scientists have genetically programmed embryonic stem cells to become nerve cells when transplanted into the brain. The research, an important step toward developing new treatments for stroke, Alzheimer's, Parkinson's and other neurological conditions showed that mice afflicted by stroke showed tangible therapeutic improvement following transplantation of these cells.
Scientists at the Burnham Institute for Medical Research have shown that neural stem cell development may be linked to Autism. The study demonstrated that mice lacking the myocyte enhancer factor 2C protein in neural stem cells had smaller brains, fewer nerve cells and showed behaviors similar to those seen in humans with a form of autism known as Rett Syndrome.
Burnham Institute announced that Dr. Stuart A. Lipton, professor and director of the Del E. Webb Neuroscience, Aging, and Stem Cell Research Center at Burnham, has been awarded $8 million from the NIH, over five years, to establish a Center for Neurodegeneration Science. The center will study potential environmental causes of Parkinson's disease.
Recent developments at the Burnham Institute for Medical Research. 1) $98 Million Dollar Grant Supports Drug Discovery; 2) Kill Cancer Cells with the Flip of a Switch; 3) What HIV Needs; 4) Burnham: the Next Generation; 5) Deep Diving for Drug Discovery
Burnham Institute for Medical Research (Burnham) announced the election of five new members to its board of trustees. These new trustees bring a wide variety of business, legal and philanthropic experience to Burnham.
Researchers at the Burnham Institute for Medical Research (Burnham) have shown in both fruit flies and humans that genes involved in embryonic heart development are also integral to adult heart function. The study, led by Rolf Bodmer, Ph.D., was published in Proceedings of National Academy of Sciences.
HeadNorth Foundation has pledged $975,000 to Burnham Institute for Medical Research to support cutting-edge stem cell research.
1) Enzyme May Hold the Key to Muscular Dystrophy; 2) Microscopic Race for New Cures; 3) Nanoworms Make Tumors Squirm; 4) Choking Out Cancer.
Burnham Institute for Medical Research (Burnham) has announced the election of Peter Preuss to its board of trustees. Preuss, president and founder of The Preuss Foundation, brings expertise in business, philanthropy and science to Burnham.
Scientists at Burnham Institute for Medical Research have demonstrated important new roles for the protein kinase complex Cdc7/Dbf4 or Cdc7/Drf1 (Ddk) in monitoring damage control during DNA replication and reinitiating replication following DNA repair.
Scientists at Burnham Institute for Medical Research (Burnham) have determined the structure of the interactions between proteins that form the heart of the death inducing signaling complex (DISC), which is responsible for triggering apoptosis (programmed cell death).
Researchers at the Burnham Institute for Medical Research have shown that search algorithms used in digital communications can help scientists identify effective multi-drug combinations.
San Diego philanthropist Conrad Prebys will donate $10 million to Burnham Institute for Medical Research to support the activities of Burnham's drug discovery center, which is part of the world's largest public drug discovery effort.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right